Healio

Postnatal hemolytic disease management varies significantly worldwide, consensus needed

Please provide your email address to receive an email when new articles are posted on . Practice patterns vary widely for management of hemolytic disease of the fetus and newborn (HDFN). Researchers ...
Nasdaq

Groundbreaking nipocalimab study of pregnant individuals at high risk for early onset severe hemolytic disease of the fetus and newborn published in The New England Journal of ...

Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a live birth at or after 32 weeks without the need for intrauterine ...
Healio

Nipocalimab delays, prevents transfusions for pregnancies at risk for hemolytic disease

Please provide your email address to receive an email when new articles are posted on . Among pregnant women who received nipocalimab infusions, 54% had live births without an intrauterine transfusion ...

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an ...

Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistically significant durable ...